3 assets in Urethra Squamous Cell Carcinoma

Therapeutic assets addressing Urethra Squamous Cell Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Ipilimumab Urethra Squamous Cell Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Urethra Squamous Cell Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Evolve104 Urethra Squamous Cell Carcinoma	EvolveImmune United, Inc	P1	CC (43)